The FDA has banned products from a Chinese API maker and suggested it get a consultant to direct upgrades after an inspection found serious problems in its manufacturing processes, some of which had ...
On arrival for a pre-approval inspection for a Chinese heparin API maker, an FDA inspector was told that the plant had not started making products and was only doing equipment testing. The truth of ...
An arm of the private equity firm TPG will invest $30 million in Solara Active Pharma, a maker of active pharmaceutical ingredients (APIs). Solara has five manufacturing sites and two research centers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results